247 related articles for article (PubMed ID: 30043421)
1. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
4. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
[TBL] [Abstract][Full Text] [Related]
5. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
Tomlinson DC; Hurst CD; Knowles MA
Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
[TBL] [Abstract][Full Text] [Related]
6. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
7. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma.
Shin K; Lim A; Odegaard JI; Honeycutt JD; Kawano S; Hsieh MH; Beachy PA
Nat Cell Biol; 2014 May; 16(5):469-78. PubMed ID: 24747439
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
9. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
10. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
[TBL] [Abstract][Full Text] [Related]
11.
Kacew A; Sweis RF
Front Immunol; 2020; 11():575258. PubMed ID: 33224141
[No Abstract] [Full Text] [Related]
12. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
14. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
[TBL] [Abstract][Full Text] [Related]
15. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
Knowles MA
World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
17. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
di Martino E; Alder O; Hurst CD; Knowles MA
Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
[TBL] [Abstract][Full Text] [Related]
18. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
19. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
